Major depressive disorder

Common Name(s)

Major depressive disorder, Major depression

Major depressive disorder is a serious form of depression which involves some combination of the following symptoms: sadness, inability to concentrate, difficulty sleeping (insomnia) or sleeping too much, feeling very tired (fatigue), weight gain or loss, irritability, loss of interest or pleasure in activities, feelings of guilt, worthlessness or hopelessness, and thoughts of suicide. It affects a person’s thoughts, moods, behavior and physical health. A major depressive episode usually lasts more than 2 weeks and interferes with a person’s ability to perform daily functions. Some people may only experience one episode, but others may experience multiple episodes in their lifetime. The cause of major depressive disorder is unknown. It may affect anyone of any age, race, ethnicity, gender or socioeconomic level. Certain factors increase a person’s risk including experiencing traumatic or stressful event(s), having a serious or chronic illness or anxiety related disorder, or having a family history of depression. Those who abuse alcohol or drugs are also at an increased risk.

Major depressive disorder is a serious illness. Without treatment an episode may continue with symptoms becoming increasingly more serious. Major depressive episodes may lead a person to feel that life is not worth living and to commit suicide. If you or someone you know is having thoughts of suicide call a suicide hot line or go to an emergency medical center. It is important to realize that depression is treatable. Treatment may include support groups, medication, talk therapy, or other strategies. Talk to your doctor to decide on the best treatment options if you or a family member is affected by major depression. Support groups are also a good source of up to date information and can help connect you with others affected by depression. See also depression.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Major depressive disorder" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Major depressive disorder" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Major depressive disorder" returned 607 free, full-text research articles on human participants. First 3 results:

Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
 

Author(s): Harry A Croft, Nunzio Pomara, Carl Gommoll, Dalei Chen, Rene Nunez, Maju Mathews

Journal: J Clin Psychiatry. 2014 Nov;75(11):e1291-8.

 

Vilazodone is a potent serotonin (5-HT) reuptake inhibitor and 5-HT₁A receptor partial agonist approved by the US Food and Drug Administration for the treatment of major depressive disorder (MDD) in adults. This study evaluated the efficacy and tolerability of vilazodone in the treatment of MDD.

Last Updated: 4 Dec 2014

Go To URL
Prolidase activity and oxidative stress in patients with major depressive disorder.
 

Author(s): Mehmet Hanifi Kokacya, Bulent Bahceci, Ilkay Bahceci, Aziz Ramazan Dilek, Recep Dokuyucu

Journal: Psychiatr Danub. 2014 Dec;26(4):314-8.

 

The aim of the current study was to determine whether the serum prolidase levels are associated with the etiopathogenesis of depression.

Last Updated: 7 Nov 2014

Go To URL
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.
 

Author(s): David L Dunner, Scott T Aaronson, Harold A Sackeim, Philip G Janicak, Linda L Carpenter, Terrence Boyadjis, David G Brock, Dafna Bonneh-Barkay, Ian A Cook, Karl Lanocha, H Brent Solvason, Mark A Demitrack

Journal: J Clin Psychiatry. 2014 Dec;75(12):1394-401.

 

Transcranial magnetic stimulation (TMS) is an effective and safe acute treatment for patients not benefiting from antidepressant pharmacotherapy. Few studies have examined its longer term durability. This study assessed the long-term effectiveness of TMS in naturalistic clinical practice ...

Last Updated: 1 Jan 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Major depressive disorder" returned 81 free, full-text review articles on human participants. First 3 results:

Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment.
 

Author(s): Raymond W Lam, Sidney H Kennedy, Roger S Mclntyre, Atul Khullar

Journal: Can J Psychiatry. 2014 Dec;59(12):649-54.

 

Last Updated: 23 Feb 2015

Go To URL
Differential diagnosis of bipolar disorder and major depressive disorder.
 

Author(s): R M Hirschfeld

Journal: J Affect Disord. 2014 Dec;169 Suppl 1():S12-6.

 

Patients with bipolar disorder spend approximately half of their lives symptomatic and the majority of that time suffering from symptoms of depression, which complicates the accurate diagnosis of bipolar disorder.

Last Updated: 23 Dec 2014

Go To URL
Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review.
 

Author(s): Richard S E Keefe, Shawn M McClintock, Robert M Roth, P Murali Doraiswamy, Steven Tiger, Manisha Madhoo

Journal: J Clin Psychiatry. 2014 Aug;75(8):864-76.

 

Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission. This review examined pharmacotherapy effects on cognitive function in MDD.

Last Updated: 6 Sep 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
 

Status: Recruiting

Condition Summary: Major Depressive Disorder; Major Depressive Disorder, Recurrent, Unspecified; Major Depressive Disorder, Single Episode, Unspecified

 

Last Updated: 1 Nov 2014

Go to URL
Study to Treat Major Depressive Disorder (MDD) With a New Medication
 

Status: Not yet recruiting

Condition Summary: Major Depressive Disorder; Depression

 

Last Updated: 23 May 2014

Go to URL
Major Depressive Disorder - Understanding The Link Between The Brain And The Heart
 

Status: Recruiting

Condition Summary: Major Depressive Disorder

 

Last Updated: 16 Dec 2013

Go to URL